arrow
R

Robert W. Kaminski

latham biopharm group
H指数:26
被引数:2,061

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multifunctional antibody responses from a primate Shigella outbreak inform vaccine design

灵长类志贺氏菌暴发产生的多功能抗体反应为疫苗设计提供信息

2026-09-020
PRE
Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study

肯尼亚婴儿中合成多糖偶联疫苗SF2a-TT15针对志贺氏菌2a型(Shigella flexneri 2a)的安全性和免疫原性:一项2a期、年龄递减、剂量递增、双盲、随机、安慰剂对照研究

2026-08-190
OAAI
Corrigendum to “Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines” [Vaccine 68 (2025) 127896]

勘误:“Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines” [Vaccine 68 (2025) 127896]

Vaccine
IF3.5
2025-12-010
OAAI
An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs

O-特异性多糖志贺菌3a型偶联疫苗在豚鼠中具有免疫原性,并能抵抗致病性角膜结膜炎的挑战。

2025-10-010
PRE
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation

侵袭性非伤寒沙门氏菌(iNTS)疾病及iNTS疫苗使用案例与需求的现状分析:世界卫生组织(WHO)专家咨询报告

VACCINE
IF3.5
2025-05-010
OAAI
WHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries

WHO 工作坊报告:为低收入和中等收入国家儿童使用的志贺氏菌疫苗提供临床路径的监管科学

2025-04-230
OA
Exploring Natural Immune Responses to Shigella Exposure Using Multiplex Bead Assays on Dried Blood Spots in High-Burden Countries: Protocol From a Multisite Diarrhea Surveillance Study
2024-03-252
OAAI
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults
2021-09-0142
OAAI
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
2021-04-0149
OAAI
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
2021-04-0133
OAAI